Pharmacological Modulation of Hemodynamic Responses During Tracheal Extubation: A Narrative Review of Intravenous Magnesium Sulphate and Esmolol

Abstract

Background:
Tracheal extubation is frequently accompanied by sympathetic stimulation, resulting in tachycardia, hypertension, coughing, and airway irritation. Although these responses are usually transient, they may precipitate serious cardiovascular, neurological, or surgical complications in high-risk patients. Pharmacological modulation is therefore an important component of safe extubation, with magnesium sulphate and esmolol commonly used due to their favourable haemodynamic profiles.

Methods:
A narrative review of published clinical trials, randomized controlled studies, meta-analyses, and review articles was conducted to evaluate the efficacy and safety of intravenous magnesium sulphate and esmolol for attenuation of haemodynamic responses during tracheal extubation. Evidence on mechanisms of action, dosing strategies, comparative effectiveness, and use in special patient populations was synthesized.

Results:
Both magnesium sulphate and esmolol effectively attenuate extubation-related haemodynamic responses. Magnesium maintains heart rate and blood pressure closer to baseline while providing bronchodilation and analgesic sparing, with minimal respiratory depression. Esmolol produces rapid and pronounced suppression of heart rate and blood pressure, offering superior control of tachycardia and hypertension but with a higher risk of bradycardia. Comparative studies suggest differing clinical advantages based on patient profile and surgical context.

Conclusion:
Intravenous magnesium sulphate and esmolol are effective agents for controlling haemodynamic responses during tracheal extubation. Agent selection should be individualized, balancing the need for haemodynamic stability, airway protection, and patient-specific comorbidities.